Recently updated results from the KEYNOTE-52 trial, with up to 5 years of follow-up, showed a median OS of 11.3 months and 4-year OS rate of 19.0% among all cisplatin-ineligible patients treated with pembrolizumab; however, in patients with high PD-L1 expression (defined as a combined positive score ≥ 10 [assessed as the number of PD-L1–stained tumour cells and immune cells relative to the total number of tumour cells]), median OS was 18.5 months with a 4-year OS rate of 31.9% [28]. This evidence concerns the gene CD274 and neoplasm.